New Data Support Strong Clinical Profile of Vitrakvi® (larotrectinib) for Adult and Pediatric Patients with TRK Fusion Cancer, Including Lung and Thyroid Tumors

Credit: Business Wire- Published 1 week ago
WHIPPANY, N.J.--(BUSINESS WIRE)--Updated clinical data for Vitrakvi® (larotrectinib) reinforce the consistent, long-term efficacy and established safety profile in an integrated dataset of 175 adult and pediatric patients with tropomyosin receptor kinase (TRK) fusion cancer.1 In addition, new tumor type specific sub-analyses in lung and thyroid cancer patients further emphasize these durable responses with no new safety signals reported.2,3 These results are being presented at the ESMO Virtual

You are here

You might like